Investigators observe no significant difference between the surgical approaches in 1-year progression rates.
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
New findings suggest that Lactobacillus bacteria in the tumors of patients with non-muscle invasive bladder cancer increase uptake of bacillus Calmette-Guérin.
The implant is wirelessly powered and modulated by an external wearable ankle unit.
Some studies show that use of transurethral resection of the prostate, long the gold standard for managing enlarged prostates, is in decline, but it still remains the most popular choice among surgeons amid a wide range of options.
The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.
The debate was highlighted at the American Urological Association’s 2023 Annual Scientific Meeting.
Investigators report results from the phase 3 randomized EMBARK trial.
Finding is based on a meta-analysis of 14 high-quality studies involving 19,365 patients.
The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.
Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.
With effective modern systemic therapies for metastatic RCC, how cytoreductive nephrectomy affects quality of life has become an increasingly relevant question, according to investigators.
Men diagnosed with prostate cancer during 2020, the start of the pandemic, were more likely to have higher-stage and higher-grade disease compared with men diagnosed in 2018-2019, according to investigators.
Investigators analyzed survey results from 495 patients with newly diagnosed localized prostate cancer.
Patients undergoing the operation in 2015-2019 vs 2005-2009 are less likely to have major surgical complications or die within 90 days, according to a study.
Renal function declines slightly in the first year of follow-up and then remains stable through 10 years.
No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.
Cardiovascular disease is a leading cause of noncancer death in men with prostate cancer.
The risk for biochemical recurrence of prostate cancer after external beam radiation therapy varies by prostate cancer risk category.
Study findings support AUA guidelines to consider antibiotic prophylaxis at the time of catheter removal.